Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Kyowa Hakko Kirin Pharma, Inc.
Sponsor:
Information provided by (Responsible Party):
Kyowa Hakko Kirin Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01626664
First received: June 19, 2012
Last updated: October 27, 2014
Last verified: October 2014

June 19, 2012
October 27, 2014
June 2012
June 2015   (final data collection date for primary outcome measure)
Overall Response Rate [ Time Frame: every 8 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01626664 on ClinicalTrials.gov Archive Site
  • progression free survival [ Time Frame: From date of randomization until the date of first documented progression, start of alternative therapy, or date of death from any cause, whichever came first, up to 36 months ] [ Designated as safety issue: No ]
  • overall survival [ Time Frame: up to 36 months ] [ Designated as safety issue: No ]
  • Quality of Life assessments [ Time Frame: up tp 36 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).

CCR4 expression in ATL patients has been demonstrated to be very high and has been associated with shorter survival compared with CCR4-negative patients. KW-0761, a monoclonal antibody targeted to CCR4, has been shown to be safe and tolerable in several clinical trials in subjects with a variety of T-cell malignancies, including ATL, mycosis fungoides and Sézary syndrome. The objective of this study is to estimate the overall response rate of KW-0761 for subjects with relapsed or refractory ATL.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Adult T-cell Leukemia-Lymphoma
  • Biological: KW-0761
    1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
    Other Names:
    • mogamulizumab
    • POTELIGEO®
  • Drug: investigator's choice (pralatrexate; gemcitabine/oxaliplatin; dexamethasone/cisplatin/cytarabine)
    • pralatrexate (30 mg/m2 weekly for 3 weeks until progression)
    • gemcitabine plus oxaliplatin (gemcitabine 1000 mg/m2, oxaliplatin 100 mg/m2 every 2 weeks until progression)
    • DHAP (dexamethasone 40 mg on day 1-4, cisplatin 100 mg/m2, cytarabine 2000 mg/m2 every 4 weeks until progression)
    Other Names:
    • Folotyn
    • Gemzar
    • Eloxitin
  • Experimental: KW-0761
    anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
    Intervention: Biological: KW-0761
  • Active Comparator: investigator's choice
    Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
    Intervention: Drug: investigator's choice (pralatrexate; gemcitabine/oxaliplatin; dexamethasone/cisplatin/cytarabine)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
70
August 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and female subjects ≥ 18 years of age
  • Confirmed diagnosis of ATL (excluding smoldering subtype)
  • Subjects must currently have evidence of disease in at least one of the following:

    • Lymph nodes
    • Extranodal masses
    • Spleen or liver
    • Skin
    • Peripheral blood
    • Bone marrow
  • Relapsed or refractory after at least one prior systemic therapy regimen for ATL;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry
  • resolution of all clinically significant toxic effects of prior cancer therapy to grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI-CTCAE, v.4.0)
  • adequate hematological, hepatic and renal function

Exclusion Criteria:

  • Smoldering subtype of ATL;
  • Lymphomatous or acute subtype subject with > 2 prior systemic therapy regimens and who has not achieved a response (CR or PR) or maintained stable disease for at least 12 weeks on last immediate prior therapy;
  • History of allogeneic transplant;
  • Autologous hematopoietic stem cell transplant within 90 days of study entry;
  • Untreated human immunodeficiency virus (HIV)
  • Has known hepatitis C. Patients who are hepatitis C antibody positive but are hepatitis C quantitative PCR negative may be enrolled;
  • Has hepatitis B based on PCR testing for hepatitis B virus DNA. Patients who are hepatitis B core antibody positive but PCR negative may be enrolled if placed on appropriate anti-hepatitis B virus prophylaxis prior to commencing treatment with KW-0761. Patients who are hepatitis B core antibody positive based on prior vaccination need not receive prophylaxis;
  • Have had a malignancy in the past two years except non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current PSA < 0.1 µg/mL, treated thyroid cancer or cervical carcinoma in situ or ductal/lobular carcinoma in situ of the breast who is currently without evidence of disease;
  • Clinical evidence of central nervous system (CNS) involvement or metastasis. In subjects suspected of having CNS disease, an MRI of the brain and/or lumbar puncture should be done to confirm;
  • Psychiatric illness, disability or social situation that would compromise the subject's safety or ability to provide consent, or limit compliance with study requirements;
  • Significant uncontrolled intercurrent illness
  • Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins;
  • Known active autoimmune diseases will be excluded (For example; Grave's disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease);
  • Is pregnant (confirmed by beta human chorionic gonadotrophin [β-HCG]) or lactating.
  • Prior treatment with KW-0761;
  • Initiation of treatment with systemic corticosteroids while on study is only permitted for acute and brief complications of underlying disease (e.g., hypercalcemia) or for treatment related side effects (e.g., including pre-medication for infusion reaction, nausea and vomiting). Subjects on systemic corticosteroids prior to enrollment must be off for 7 days before initiation of study treatment, unless specifically indicated for the treatment of hypercalcemia. (subjects may receive inhalation corticosteroids and replacement doses of systemic corticosteroids as needed);
  • Initiation of treatment with topical corticosteroids while on study is not permitted except to treat an acute rash. Subjects on a stable dose of medium or low potency topical corticosteroids for at least 4 weeks prior to Pre-treatment Visit may continue use at the same dose, although the investigator should attempt to taper the use to lowest dose tolerable;
  • Have had interferon-α and/or zidovudine within 1 week, or anti-neoplastic chemotherapy, radiation, immunotherapy, or investigational medications within 2 weeks of first study treatment;
  • Subjects on any immunomodulatory drug. Subjects on any immunomodulatory drug within 4 weeks of their first dose of KW-0761 are also excluded.
Both
18 Years and older
No
Contact: Kyowa Hakko Kirin Pharma 1-609-919-1100 clinical.info@kyowa-kirin-pharma.com
United States,   Belgium,   Brazil,   France,   Peru,   United Kingdom
 
NCT01626664
PROTOCOL 0761-009
No
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Hakko Kirin Pharma, Inc.
Not Provided
Study Director: Michael Kurman, MD Kyowa Hakko Kirin Pharma, Inc.
Kyowa Hakko Kirin Pharma, Inc.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP